{
  "nctId": "NCT04075318",
  "briefTitle": "Study of UB-312 in Healthy Participants and Parkinson's Disease Patients",
  "officialTitle": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease",
  "protocolDocument": {
    "nctId": "NCT04075318",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2022-04-14",
    "uploadDate": "2025-02-13T11:00",
    "size": 399455,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04075318/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 70,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-08-29",
    "completionDate": "2023-03-01",
    "primaryCompletionDate": "2023-03-01",
    "firstSubmitDate": "2019-08-05",
    "firstPostDate": "2019-08-30"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Male or female aged 40 to 85 years old, inclusive at screening\n* Expected to be able to undergo all study procedures\n* Other inclusion criteria apply\n\nFor Part B only:\n\n* A diagnosis of PD, confirmed by a neurologist\n* Hoehn \\&Yahr Stage ≤ III at Screening\n* Stable treatment of permitted antiparkinsonian medications from 30 days prior to first study drug administration or 60 days for MAO-B inhibitors, and expected to remain stable throughout the study\n\nExclusion Criteria:\n\n* Clinically significant abnormalities, as judged by the investigator\n* History of medical, neurological or psychiatric conditions which in the opinion of the investigator may compromise participant's safety or scientific value of the study\n* Acute or chronic infection as judged by the investigator, for positive human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)\n* History or evidence of an autoimmune disorder\n* History of anergy.\n* Participated/participating in any clinical trial with monoclonal antibodies or vaccines directed at aSyn\n* Other exclusion criteria apply\n\nFor Part B only:\n\n* Other known or suspected cause of Parkinsonism other than idiopathic PD\n* History or evidence at Screening of PD-related freezing episodes, falls, or orthostatic hypotension\n* Dopamine transporter single-photon emission computerized tomography scan (DaTscan) inconsistent with dopamine transporter deficit.\n* Clinically significant neurological disease other than PD",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "85 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Frequency of Adverse Events",
        "description": "Number of AEs will be assessed",
        "timeFrame": "44 weeks"
      },
      {
        "measure": "Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood",
        "description": "Number of Participants with Anti-aSyn Antibodies in Blood from Weeks 1 through 45.",
        "timeFrame": "44 weeks"
      },
      {
        "measure": "Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in CSF",
        "description": "Number of Participants with Anti-aSyn Antibodies in CSF from Weeks 1 through 45.",
        "timeFrame": "44 weeks"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 3,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 59,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:45.974Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}